Author Correction: CFIm25 links alternative polyadenylation to glioblastoma tumour suppression (Nature, (2014), 510, 7505, (412-416), 10.1038/nature13261);CFIm25 links alternative polyadenylation to glioblastoma tumour suppression

Nature

Volumn 510, Issue 7505, 2014, Pages 412-416

  Masamha, Chioniso P ^a   Xia, Zheng ^b   Yang, Jingxuan ^a   Albrecht, Todd R ^a   Li, Min ^a   Shyu, Ann Bin ^a   Li, Wei ^b   Wagner, Eric J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Department of Molecular and Cellular Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GLUTAMINASE; METHYL CPG BINDING PROTEIN 2; SMALL INTERFERING RNA;

GENE EXPRESSION; GOLD; GROWTH; INHIBITION; PUBLIC HEALTH; RNA; TUMOR;

3' UNTRANSLATED REGION; ALGORITHM; ALTERNATIVE POLYADENYLATION; AMPLICON; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CLEAVAGE FACTOR IIM25 GENE; CONTROLLED STUDY; CYCLIN D1 GENE; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLUTAMINASE GENE; HUMAN; HUMAN CELL; METHYL CPG BINDING PROTEIN 2 GENE; ONCOGENE; POLYADENYLATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; STOP CODON; TUMOR VOLUME; UPREGULATION;

3' UNTRANSLATED REGIONS; ANIMALS; CARCINOGENESIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HELA CELLS; HETEROGRAFTS; HUMANS; MALE; MICE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; POLYADENYLATION; REGRESSION ANALYSIS; RNA, MESSENGER;

EID: 84903129276     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-022-05459-6     Document Type: Erratum

References (39)

1. Elkon, R. et al. E2F mediates enhanced alternative polyadenylation in proliferation. Genome Biol. 13, R59 (2012).
2. Sandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A. & Burge, C. B. Proliferating cells express mRNAs with shortened 39 untranslated regions and fewer microRNA target sites. Science 320, 1643-1647 (2008).
3. Mayr, C. & Bartel, D. P. Widespread shortening of 39UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673-684 (2009).
4. Ji, Z., Lee, J. Y., Pan, Z., Jiang, B. & Tian, B. Progressive lengthening of 39 untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. Proc. Natl Acad. Sci. USA 106, 7028-7033 (2009).
5. Mangone, M. et al. The landscape of C. elegans 39UTRs. Science 329, 432-435 (2010).
6. Tian, B., Hu, J., Zhang, H. & Lutz, C. S. A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res. 33, 201-212 (2005).
7. Di Giammartino, D. C., Nishida, K. & Manley, J. L. Mechanisms and consequences of alternative polyadenylation. Mol. Cell 43, 853-866 (2011).
8. Chen, C. -Y. A. & Shyu, A. -B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20, 465-470 (1995).
9. Farh, K. K. et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310, 1817-1821 (2005).
10. Wu, L. & Belasco, J. G. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol. Cell 29, 1-7 (2008).
11. Singh, P. et al. Global changes in processing of mRNA 39 untranslated regions characterize clinically distinct cancer subtypes. Cancer Res. 69, 9422-9430 (2009).
12. Kubo, T., Wada, T., Yamaguchi, Y., Shimizu, A. & Handa, H. Knock-down of 25 kDa subunit of cleavage factor Im in Hela cells alters alternative polyadenylation within 39-UTRs. Nucleic Acids Res. 34, 6264-6271 (2006).
13. Yao, C. et al. Transcriptome-wide analyses of CstF64-RNA interactions in global regulation of mRNA alternative polyadenylation. Proc. Natl Acad. Sci. USA 109, 18773-18778 (2012).
14. Martin, G., Gruber, A. R., Keller, W. & Zavolan, M. Genome-wide analysis of premRNA 39 end processing reveals a decisive role of human cleavage factor I in the regulation of 39UTR length. Cell Reports 1, 753-763 (2012).
15. Thomas, P. E. et al. Genome-wide control of polyadenylation site choice byCPSF30 in Arabidopsis. Plant Cell 24, 4376-4388 (2012).
16. Jan, C. H., Friedman, R. C., Ruby, J. G. & Bartel, D. P. Formation, regulation and evolution of Caenorhabditis elegans 39UTRs. Nature 469, 97-101 (2011).
17. Shepard, P. J. et al. Complex and dynamic landscape of RNA polyadenylation revealed by PAS-Seq. RNA 17, 761-772 (2011).
18. Bernard, D. et al. The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth. Oncogene 25, 1358-1366 (2006).
19. Sicinski, P. et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82, 621-630 (1995).
20. Weinstat-Saslow, D. et al. Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas fromnon-malignant lesions. Nature Med. 1, 1257-1260 (1995).
21. Liu, W. et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl Acad. Sci. USA 109, 8983-8988 (2012).
22. Wang, J. B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010).
23. Klein, M. E. et al. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nature Neurosci. 10, 1513-1514 (2007).
24. Deshpande, A. et al. 39UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle 8, 3592-3600 (2009).
25. Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009).
26. Miura, P., Shenker, S., Andreu-Agullo, C., Westholm, J. O. & Lai, E. C. Widespread and extensive lengthening of 39 UTRs in the mammalian brain. Genome Res. 23, 812-825 (2013).
27. Ulitsky, I. et al. Extensive alternative polyadenylation during zebrafish development. Genome Res. 22, 2054-2066 (2012).
28. Nakayama, T. et al. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene 27, 3221-3232 (2008).
29. Wagner, E. J. & Garcia-Blanco, M. A. RNAi-mediated PTB depletion leads to enhanced exon definition. Mol. Cell 10, 943-949 (2002).
30. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
31. Ward, A. & Dutton, J. R. Regulation of the Wilms' tumour suppressor (WT1) gene by an antisense RNA: a link with genomic imprinting? J. Pathol. 185, 342-344 (1998).
32. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoformswitching during cell differentiation. Nature Biotechnol. 28, 511-515 (2010).
33. Kaplan, P. J., Mohan, S., Cohen, P., Foster, B. A. & Greenberg, N. M. The insulinlike growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 59, 2203-2209 (1999).
34. Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation ofmRNAtranslation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379 (2010).
35. Braulke, T., Dittmer, F., Gotz, W. & von Figura, K. Alteration in pancreatic immunoreactivity of insulin-like growth factor (IGF)-binding protein (IGFBP)-6 and in intracellular degradation of IGFBP-3 in fibroblasts of IGF-II receptor/IGF-II-deficient mice. Horm. Metab. Res. 31, 235-241 (1999).
36. Hu, J. F. et al. Lack of reciprocal genomic imprinting of sense and antisense RNA of mouse insulin-like growth factor II receptor in the central nervous system. Biochem. Biophys. Res. Commun. 257, 604-608 (1999).
37. Ellis, M. J. et al. Insulin-like growth factors in human breast cancer. Breast Cancer Res. Treat. 52, 175-184 (1998).
38. Friedman, R. C., Farh, K. K. -H., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105 (2009).
39. Gómez-Angelats, M., Teeguarden, J. G., Dragan, Y. P. & Pitot, H. C. Mutational analysis of three tumor suppressor genes in two models of rat hepatocarcinogenesis. Mol. Carcinog. 25, 157-163 (1999).